Liquid Markers for Risk Stratification of Pulmonary Nodules, Ready for Prime Time? Yes!
作者信息
Kim Roger Y, Sears Catherine R, Pastis Nicholas J
机构信息
Division of Pulmonary, Allergy and Critical Care (R. Y. K.), Department of Medicine, University of Pennsylvania, Philadelphia, PA; the Division of Pulmonary, Critical Care, Sleep and Occupational Medicine (C. R. S.), Department of Medicine, Indiana University School of Medicine, Indianapolis, IN; the Division of Pulmonary Medicine (C. R. S.), Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, IN; and the Division of Pulmonary, Critical Care and Sleep Medicine (N. J. P.), Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH.
出版信息
CHEST Pulm. 2024 Sep;2(3). doi: 10.1016/j.chpulm.2024.100071. Epub 2024 Jun 11.
Abstract
摘要
相似文献
1
Liquid Markers for Risk Stratification of Pulmonary Nodules, Ready for Prime Time? Yes!
CHEST Pulm. 2024 Sep;2(3). doi: 10.1016/j.chpulm.2024.100071. Epub 2024 Jun 11.
2
Tumour-pleura relationship on computed tomography (CT) provides effective risk stratification for peripheral pulmonary nodules with Lung Imaging Reporting and Data System (Lung-RADS) score of 4X.
Quant Imaging Med Surg. 2024 Oct 1;14(10):7138-7150. doi: 10.21037/qims-24-530. Epub 2024 Sep 21.
3
Spiral computed tomography for stratification of pulmonary embolism: ready for prime time?
Eur Respir J. 2014 Jun;43(6):1554-5. doi: 10.1183/09031936.00038414.
4
Novel Left Atrial Markers for Risk Stratification of Heart Failure: Ready for Prime Time?
J Am Coll Cardiol. 2022 Apr 26;79(16):1562-1564. doi: 10.1016/j.jacc.2022.02.023.
5
Radiomics and artificial intelligence for risk stratification of pulmonary nodules: Ready for primetime?
Cancer Biomark. 2024 Feb 6:CBM230360. doi: 10.3233/CBM-230360.
6
Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: YES.
Mult Scler. 2022 Aug;28(9):1324-1326. doi: 10.1177/13524585211062173.
7
Non-invasive diagnosis of pulmonary nodules by circulating tumor DNA methylation: A prospective multicenter study.
Lung Cancer. 2024 Sep;195:107930. doi: 10.1016/j.lungcan.2024.107930. Epub 2024 Aug 11.
8
Clinical trials: is the Bayesian approach ready for prime time? Yes!
Stroke. 2005 Jul;36(7):1621-2. doi: 10.1161/01.STR.0000170637.02692.14. Epub 2005 Jun 9.
9
Cardiac magnetic resonance for the risk stratification of heart transplant recipients: ready for prime time?
J Thorac Dis. 2015 Apr;7(4):560-1. doi: 10.3978/j.issn.2072-1439.2015.03.01.
10
EUS-guided biliary drainage: is it ready for prime time? Yes!
Gastrointest Endosc. 2013 Jul;78(1):102-5. doi: 10.1016/j.gie.2013.03.004.
本文引用的文献
1
Update on Biomarkers for the Stratification of Indeterminate Pulmonary Nodules.
Chest. 2023 Oct;164(4):1028-1041. doi: 10.1016/j.chest.2023.05.025. Epub 2023 May 25.
2
Guided Bronchoscopy for the Evaluation of Pulmonary Lesions: An Updated Meta-analysis.
Chest. 2023 Jun;163(6):1589-1598. doi: 10.1016/j.chest.2022.12.044. Epub 2023 Jan 11.
3
Percepta Genomic Sequencing Classifier and decision-making in patients with high-risk lung nodules: a decision impact study.
BMC Pulm Med. 2022 Jan 6;22(1):26. doi: 10.1186/s12890-021-01772-4.
4
Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
JAMA. 2021 Mar 9;325(10):971-987. doi: 10.1001/jama.2021.0377.
5
Effect of a Rule-in Biomarker Test on Pulmonary Nodule Management: A Survey of Pulmonologists and Thoracic Surgeons.
Clin Lung Cancer. 2020 Mar;21(2):e89-e98. doi: 10.1016/j.cllc.2019.05.004. Epub 2019 Jun 13.
6
Models to Estimate the Probability of Malignancy in Patients with Pulmonary Nodules.
Ann Am Thorac Soc. 2018 Oct;15(10):1117-1126. doi: 10.1513/AnnalsATS.201803-173CME.
7
Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial.
Chest. 2018 Sep;154(3):491-500. doi: 10.1016/j.chest.2018.02.012. Epub 2018 Mar 1.
8
Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement.
Am J Respir Crit Care Med. 2017 Oct 1;196(7):e15-e29. doi: 10.1164/rccm.201708-1678ST.
9
Physician Assessment of Pretest Probability of Malignancy and Adherence With Guidelines for Pulmonary Nodule Evaluation.
Chest. 2017 Aug;152(2):263-270. doi: 10.1016/j.chest.2017.01.018. Epub 2017 Jan 20.
10
Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer.
J Thorac Oncol. 2017 Mar;12(3):578-584. doi: 10.1016/j.jtho.2016.08.143. Epub 2016 Sep 8.
Zotero 插件